2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1010

Catecholaminergic-to-Cholinergic Transition of Sympathetic Nerve Fibers in Arthritis and in a Co-Culture System of Sympathetic Ganglia in Vitro
Abstract Number: 836

Categorical Change in 6MWD in Patients with Connective Tissue Disease Associated Pulmonary Arterial Hypertension Receiving Ambrisentan over 3-Years
Abstract Number: 2666

Causes of Stillbirths in Women with SLE
Abstract Number: 763

Caveolin-1 and Peroxisome Proliferator-Activated Receptor Gamma Co-Regulate the Differentiation of Monocytes to Adipocytes and Myofibroblasts in Vivo and in Vitro
Abstract Number: 1748

CCR6⁺CD4⁺ Cells Are Counterparts of Follicular T-Cells Supporting Autoantibody Production in Rheumatoid Arthritis
Abstract Number: 1863

CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Abstract Number: 27

CD115⁺ Osteoclast Precursors Arise before Clinical Onset of Arthritis and Are Regulated By Proinflammatory Cytokines
Abstract Number: 1946

CD22 Is Required for Formation of Memory B Cell Precursors within Germinal Centers
Abstract Number: 2743

CD27 Is a Key Regulator of T Cell Responses
Abstract Number: 2726

CD28null T Cells from Polymyositis Patients Are Cytotoxic to Autologous Muscle Cells in Vitro Via Perforin-Dependent Mechanisms
Abstract Number: 1752

CD30 As a Target of Aptamers and Delivery Portal for Aptamer-shRNA to Block Th17 Cells
Abstract Number: 1751

CD4 Aptamer-RORγt shRNA Chimera Inhibits IL-17 Synthesis By Human CD4⁺ T cells
Abstract Number: 1744

CD4+ T Cell Subpopulations in Blood and Synovial Fluid Defined By Differential Expression of Integrins
Abstract Number: 1631

Cell Bound Complement Activation Products and Their Relationship to Disease Activity and Quality of Life Measures in Systemic Lupus Erythematosus
Abstract Number: 1924

Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].